{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:06:59Z","timestamp":1787774819907,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,2]],"date-time":"2027-01-02T00:00:00Z","timestamp":1798848000000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","award":["AID-OAA-A-17-00011"],"award-info":[{"award-number":["AID-OAA-A-17-00011"]}],"id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jconrel.2025.114575","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T22:53:22Z","timestamp":1766703202000},"page":"114575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A subcutaneous implant that releases islatravir provides long-lasting protection against vaginal SHIV infection in macaques"],"prefix":"10.1016","volume":"390","author":[{"given":"Michele B.","family":"Daly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Krovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chasity A.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Brake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng E.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lipscomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie L.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gerardo","family":"Garc\u00eda-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Dobard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jconrel.2025.114575_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"Murchu","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114575_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jconrel.2025.114575_bb0015","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.jconrel.2025.114575_bb0020","series-title":"FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection","author":"U.S. Food & Drug Administration","year":"2021"},{"key":"10.1016\/j.jconrel.2025.114575_bb0025","author":"US Department of Health and Human Services"},{"issue":"13","key":"10.1016\/j.jconrel.2025.114575_bb0030","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jconrel.2025.114575_bb0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly Lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114575_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114575_bb0045","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00781-23","article-title":"Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the <i>vastus lateralis<\/i> (lateral thigh) muscles of healthy adult participants","volume":"68","author":"Han","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114575_bb0050","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","article-title":"Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges","volume":"19","author":"Agrahari","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.114575_bb0055","article-title":"HIV preexposure prophylaxis and postexposure prophylaxis in women: a comprehensive guide for healthcare providers","volume":"11","author":"Vora","year":"2024","journal-title":"Ther. Adv. Infect Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114575_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285711","article-title":"Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: qualitative insights from women end users and health care providers in South Africa and Zimbabwe","volume":"18","author":"Nkomo","year":"2023","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114575_bb0065","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/jac\/dkac252","article-title":"Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model","volume":"77","author":"Massud","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2025.114575_bb0070","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.3390\/pharmaceutics15122676","article-title":"Pharmacokinetic study of Islatravir and Etonogestrel implants in macaques","volume":"15","author":"Daly","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114575_bb0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0000000000002755","article-title":"Safety and pharmacokinetics of once-daily multiple-dose Administration of Islatravir in adults without HIV","volume":"88","author":"Matthews","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2025.114575_bb0080","series-title":"Abstract 481. Conference on Retroviruses and Opportunistic Infections (CROI) 2019 March 4\u20137","article-title":"MK-8591 Potency and PK provide high inhibitory quotients at low dose QD and QW","year":"2019"},{"issue":"12","key":"10.1016\/j.jconrel.2025.114575_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050632","article-title":"Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen","volume":"7","author":"Radzio","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.114575_bb0090","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jiz271","article-title":"Once-weekly oral dosing of MK-8591 protects male rhesus macaques from intrarectal challenge with SHIV109CP3","volume":"221","author":"Markowitz","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2025.114575_bb0095","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Islatravir PK Threshold & Dose Selection for Monthly Oral PrEP","year":"2021"},{"issue":"702","key":"10.1016\/j.jconrel.2025.114575_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg2887","article-title":"Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates","volume":"15","author":"Pons-Faudoa","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114575_bb0105","author":"Merck & Co"},{"key":"10.1016\/j.jconrel.2025.114575_bb0110","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Modeling to optimize islatravir QW dose in HIV virologically supressed PWH","year":"2023"},{"key":"10.1016\/j.jconrel.2025.114575_bb0115","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Switch to DOR\/ISL (100\/0.25 mg) QD From BIC\/FTC\/TAF: A Blinded Phase III Study in Adults With HIV-1","year":"2025"},{"key":"10.1016\/j.jconrel.2025.114575_bb0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jconrel.2021.10.021","article-title":"Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones","volume":"340","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114575_bb0125","series-title":"International AIDS Society (IAS) Conference","article-title":"Pharmacokinetics and safety of long-acting islatravir and its novel prodrug islatravir alafenamide implants for HIV prevention","year":"2023"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114575_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101226","article-title":"Reservoir-style polymeric drug delivery systems: empirical and predictive models for implant design","volume":"15","author":"Li","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114575_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114575_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/jmp.12723","article-title":"Defining blood hematology reference values in female pig-tailed macaques (Macaca nemestrina) using the isolation Forest algorithm","volume":"53","author":"Kim","year":"2024","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.jconrel.2025.114575_bb0145","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/QAD.0000000000002390","article-title":"HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis","volume":"33","author":"Council OD","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2025.114575_bb0150","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"224","author":"Marzinke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2025.114575_bb0155","series-title":"Efficacy of Long-Acting Cabotegravir and Rilpivirine for PEP in a Macaque Model of RT SHIV Infection","first-page":"1132","author":"Srinivasan","year":"2024"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114575_bb0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/QAI.0000000000002879","article-title":"Brief report: efficacy and safety of oral Islatravir once daily in combination with Doravirine through 96 weeks for treatment-naive adults with HIV-1 infection receiving initial treatment with Islatravir, Doravirine, and lamivudine","volume":"91","author":"Molina","year":"2022","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2025.114575_bb0165","series-title":"HIVR4P","article-title":"Oral Islatravir in macaques decreases total lymphocytes and monocytes and is associated with immune dysregulation","year":"2024"},{"key":"10.1016\/j.jconrel.2025.114575_bb0170","series-title":"Materials Research Society (MRS) Conference","article-title":"Long-term in vitro degradation kinetics of novel drug-loaded poly(\u03b5-caprolactone) implants for contraception and HIV pre-exposure prophylaxis","year":"2021"},{"key":"10.1016\/j.jconrel.2025.114575_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.progpolymsci.2019.05.004","article-title":"Degradation mechanisms of polycaprolactone in the context of chemistry, geometry and environment","volume":"96","author":"Bartnikowski","year":"2019","journal-title":"Prog. Polym. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114575_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114575_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111057","article-title":"Performance and stability of tenofovir alafenamide formulations within subcutaneous biodegradable implants for HIV pre-exposure prophylaxis (PrEP)","volume":"12","author":"Li","year":"2020","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114575_bb0190","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiz383","article-title":"Efficacy of Oral tenofovir alafenamide\/emtricitabine combination or single-agent tenofovir alafenamide against vaginal simian human immunodeficiency virus infection in macaques","volume":"220","author":"Massud","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114575_bb0195","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jac\/dkac015","article-title":"Intracellular islatravir pharmacology differs between species in an in vitro model: implications for preclinical study design","volume":"77","author":"Sykes","year":"2022","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925011897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:28:16Z","timestamp":1781702896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925011897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0168365925011897"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114575","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A subcutaneous implant that releases islatravir provides long-lasting protection against vaginal SHIV infection in macaques","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114575"}}